A randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily triamcinolone acetonide (Nasacort AQ nasal spray 110 microg) on the growth velocity of children, 3 to 9 years of age, with perennial allergic rhinitis (PAR).

Trial Profile

A randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily triamcinolone acetonide (Nasacort AQ nasal spray 110 microg) on the growth velocity of children, 3 to 9 years of age, with perennial allergic rhinitis (PAR).

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jan 2015

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 06 Aug 2012 Trial phase changed from III to IV as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 28 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top